DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 51 filers reported holding DYNE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,274,819 | +42.7% | 1,035,136 | +79.2% | 1.02% | +126.3% |
| Q2 2023 | $6,498,473 | -2.3% | 577,642 | 0.0% | 0.45% | -2.8% |
| Q1 2023 | $6,654,436 | +99294.1% | 577,642 | 0.0% | 0.46% | -40.1% |
| Q4 2022 | $6,695 | -99.9% | 577,642 | 0.0% | 0.77% | -4.8% |
| Q3 2022 | $7,336,000 | +84.9% | 577,642 | 0.0% | 0.81% | +103.5% |
| Q2 2022 | $3,968,000 | -28.7% | 577,642 | 0.0% | 0.40% | +3.9% |
| Q1 2022 | $5,568,000 | -18.9% | 577,642 | 0.0% | 0.38% | -7.5% |
| Q4 2021 | $6,868,000 | -26.8% | 577,642 | 0.0% | 0.41% | -1.7% |
| Q3 2021 | $9,381,000 | -22.8% | 577,642 | 0.0% | 0.42% | -20.0% |
| Q2 2021 | $12,154,000 | +35.5% | 577,642 | 0.0% | 0.53% | +67.0% |
| Q1 2021 | $8,971,000 | +35.6% | 577,642 | +83.4% | 0.32% | +6.8% |
| Q4 2020 | $6,615,000 | +4.0% | 315,000 | 0.0% | 0.30% | -19.8% |
| Q3 2020 | $6,360,000 | – | 315,000 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |